Works matching IS 01676997 AND DT 2023 AND VI 41 AND IP 5

Results: 14

A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 751, doi. 10.1007/s10637-023-01393-0

By:

Mino, Tatsuji;
Ureshino, Hiroshi;
Ueshima, Taichi;
Kashimoto, Naoki;
Yamaguchi, Tomonori;
Naka, Kazuhito;
Inaba, Toshiya;
Ichinohe, Tatsuo

Publication type:

Article

Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 761, doi. 10.1007/s10637-023-01392-1

By:

Yamaoka, Kenta;
Irie, Kei;
Hiramoto, Nobuhiro;
Hirabatake, Masaki;
Ikesue, Hiroaki;
Hashida, Tohru;
Shimizu, Tadashi;
Ishikawa, Takayuki;
Muroi, Nobuyuki

Publication type:

Article

Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 719, doi. 10.1007/s10637-023-01391-2

By:

Gao, Zhao;
Wu, Shikai;
Yang, Yinmo;
Sun, Mingxia;
Tian, Xiaodong;
Jin, Xuan

Publication type:

Article

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 768, doi. 10.1007/s10637-023-01390-3

By:

Ke, Jun-yi;
Huang, Shu;
Jing, Zhi-tao;
Duan, Min-chao

Publication type:

Article

Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 710, doi. 10.1007/s10637-023-01389-w

By:

Ghanem, Buthainah

Publication type:

Article

Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 727, doi. 10.1007/s10637-023-01388-x

By:

Haas, Markus;
Lein, Alexander;
Fuereder, Thorsten;
Schnoell, Julia;
Brkic, Faris F.;
Liu, David T.;
Kadletz-Wanke, Lorenz;
Heiduschka, Gregor;
Jank, Bernhard J.

Publication type:

Article

Development and characterization of fused human arginase I for cancer therapy.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 652, doi. 10.1007/s10637-023-01387-y

By:

Jawalekar, Snehal Sainath;
Kawathe, Priyanka Sugriv;
Sharma, Nisha;
Anakha, J;
Tikoo, Kulbhushan;
Pande, Abhay H.

Publication type:

Article

Cytotoxicity of poly-guanidine in medulloblastoma cell lines.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 688, doi. 10.1007/s10637-023-01386-z

By:

Gallo-Oller, Gabriel;
de Ståhl, Teresita Díaz;
Alaiya, Ayodele;
Nilsson, Sten;
Holmberg, Anders R.;
Márquez-Méndez, Marcela

Publication type:

Article

Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 638, doi. 10.1007/s10637-023-01385-0

By:

Li, Lina;
Chen, Fengquan;
Li, Mengzhe;
Liao, Yongxiang;
Wang, Yongjie;
Jiang, Wen;
Luan, Yun;
Xue, Xia

Publication type:

Article

Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 699, doi. 10.1007/s10637-023-01384-1

By:

Lam, Rachel C.T.;
Hui, Connie W.C.;
Wong, C. H.;
Lo, K. W.;
Tsang, Anna C.M.;
Hui, Edwin P.;
Chan, Anthony T.C.;
Ma, Brigette B.Y.

Publication type:

Article

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 677, doi. 10.1007/s10637-023-01383-2

By:

Kristeleit, Rebecca;
Leary, Alexandra;
Delord, Jean Pierre;
Moreno, Victor;
Oaknin, Ana;
Castellano, Daniel;
Shappiro, Geoffrey I.;
Fernández, Cristian;
Kahatt, Carmen;
Alfaro, Vicente;
Siguero, Mariano;
Rueda, Daniel;
Zeaiter, Ali;
Awada, Ahmad;
Santaballa, Ana;
Zaman, Khalil;
Sehouli, Jalid;
Subbiah, Vivek

Publication type:

Article

Pharmacological assessment of the antineoplastic and immunomodulatory properties of a new spiroindolone derivative (7',8'-Dimethoxy-1',3'-dimethyl-1,2,3',4'-tetrahydrospiro[indole-3,5'-pyrazolo[3,4-c]isoquinolin]-2-one) in chronic myeloid leukemia.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 629, doi. 10.1007/s10637-023-01382-3

By:

de Castro Alves, Carlos Eduardo;
Bogza, Serge L.;
Bohdan, Nathalie;
Rozhenko, Alexander B.;
de Freitas Gomes, Alice;
de Oliveira, Regiane Costa;
de Azevedo, Renata Galvão;
Maciel, Larissa Raquel Silva;
Dhyani, Anamika;
Grafov, Andriy;
Pontes, Gemilson Soares

Publication type:

Article

A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 737, doi. 10.1007/s10637-023-01381-4

By:

Sun, Z.;
Gu, C.;
Wang, X.;
Shang, A.;
Quan, W.;
Wu, J.;
Ji, P.;
Yao, Y.;
Liu, W.;
Li, D.

Publication type:

Article

Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation.

Published in:

Investigational New Drugs, 2023, v. 41, n. 5, p. 664, doi. 10.1007/s10637-023-01372-5

By:

Pan, Mingzhu;
Liu, Yali;
Sang, Tian;
Xie, Jiajun;
Lin, Huishu;
Wei, Jianpeng;
Shao, Shuai;
Zheng, Yanying;
Zhang, Juan

Publication type:

Article